Eupraxia Pharmaceuticals Common Net Income
| EPRX Stock | 8.44 0.31 3.81% |
As of the 13th of February 2026, Eupraxia Pharmaceuticals shows the Coefficient Of Variation of 639.59, downside deviation of 2.88, and Mean Deviation of 3.03. Eupraxia Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Eupraxia Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Eupraxia Pharmaceuticals' valuation are provided below:We have found one hundred twenty available fundamental signals for Eupraxia Pharmaceuticals Common, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to verify all of Eupraxia Pharmaceuticals Common prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 70.1 M in 2026. Enterprise Value is likely to drop to about 90.7 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -23.2 M | -24.3 M | |
| Net Loss | -23.2 M | -24.3 M | |
| Net Loss | (1.18) | (1.24) | |
| Net Income Per E B T | 0.89 | 0.77 |
Eupraxia | Net Income | Build AI portfolio with Eupraxia Stock |
The evolution of Net Income for Eupraxia Pharmaceuticals Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Eupraxia Pharmaceuticals compares to historical norms and industry peers.
Latest Eupraxia Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Eupraxia Pharmaceuticals Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Eupraxia Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Eupraxia Pharmaceuticals Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Eupraxia Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eupraxia Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (25.74 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Eupraxia Net Income Regression Statistics
| Arithmetic Mean | (13,258,517) | |
| Coefficient Of Variation | (90.25) | |
| Mean Deviation | 10,144,655 | |
| Median | (4,380,755) | |
| Standard Deviation | 11,965,304 | |
| Sample Variance | 143.2T | |
| Range | 32.7M | |
| R-Value | (0.86) | |
| Mean Square Error | 40.5T | |
| R-Squared | 0.73 | |
| Significance | 0.000011 | |
| Slope | (2,031,349) | |
| Total Sum of Squares | 2290.7T |
Eupraxia Net Income History
Other Fundumenentals of Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Net Income component correlations
Eupraxia Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Eupraxia Pharmaceuticals is extremely important. It helps to project a fair market value of Eupraxia Stock properly, considering its historical fundamentals such as Net Income. Since Eupraxia Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eupraxia Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eupraxia Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eupraxia Pharmaceuticals. Projected growth potential of Eupraxia fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Eupraxia Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Eupraxia Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Eupraxia's accounting equity. The concept of intrinsic value - what Eupraxia Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Eupraxia Pharmaceuticals' price substantially above or below its fundamental value.
It's important to distinguish between Eupraxia Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Eupraxia Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Eupraxia Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Eupraxia Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Eupraxia Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Eupraxia Pharmaceuticals.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Eupraxia Pharmaceuticals on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Eupraxia Pharmaceuticals Common or generate 0.0% return on investment in Eupraxia Pharmaceuticals over 90 days. Eupraxia Pharmaceuticals is related to or competes with Mediwound, Nautilus Biotechnology, NeOnc Technologies, Orchestra BioMed, Aardvark Therapeutics, Sellas Life, and Inventiva. Eupraxia Pharmaceuticals is entity of United States More
Eupraxia Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Eupraxia Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Eupraxia Pharmaceuticals Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.88 | |||
| Information Ratio | 0.1384 | |||
| Maximum Drawdown | 24.61 | |||
| Value At Risk | (4.46) | |||
| Potential Upside | 6.98 |
Eupraxia Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eupraxia Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Eupraxia Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Eupraxia Pharmaceuticals historical prices to predict the future Eupraxia Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1352 | |||
| Jensen Alpha | 0.6314 | |||
| Total Risk Alpha | 0.3006 | |||
| Sortino Ratio | 0.2157 | |||
| Treynor Ratio | 0.816 |
Eupraxia Pharmaceuticals February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1352 | |||
| Market Risk Adjusted Performance | 0.826 | |||
| Mean Deviation | 3.03 | |||
| Semi Deviation | 2.46 | |||
| Downside Deviation | 2.88 | |||
| Coefficient Of Variation | 639.59 | |||
| Standard Deviation | 4.49 | |||
| Variance | 20.12 | |||
| Information Ratio | 0.1384 | |||
| Jensen Alpha | 0.6314 | |||
| Total Risk Alpha | 0.3006 | |||
| Sortino Ratio | 0.2157 | |||
| Treynor Ratio | 0.816 | |||
| Maximum Drawdown | 24.61 | |||
| Value At Risk | (4.46) | |||
| Potential Upside | 6.98 | |||
| Downside Variance | 8.28 | |||
| Semi Variance | 6.06 | |||
| Expected Short fall | (3.77) | |||
| Skewness | 1.93 | |||
| Kurtosis | 5.42 |
Eupraxia Pharmaceuticals Backtested Returns
Eupraxia Pharmaceuticals appears to be slightly risky, given 3 months investment horizon. Eupraxia Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.1, which denotes the company had a 0.1 % return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Eupraxia Pharmaceuticals Common, which you can use to evaluate the volatility of the firm. Please utilize Eupraxia Pharmaceuticals' Downside Deviation of 2.88, mean deviation of 3.03, and Coefficient Of Variation of 639.59 to check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Eupraxia Pharmaceuticals holds a performance score of 8. The firm shows a Beta (market volatility) of 0.85, which means possible diversification benefits within a given portfolio. As returns on the market increase, Eupraxia Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Eupraxia Pharmaceuticals is expected to be smaller as well. Please check Eupraxia Pharmaceuticals' value at risk, as well as the relationship between the kurtosis and market facilitation index , to make a quick decision on whether Eupraxia Pharmaceuticals' price patterns will revert.
Auto-correlation | 0.05 |
Virtually no predictability
Eupraxia Pharmaceuticals Common has virtually no predictability. Overlapping area represents the amount of predictability between Eupraxia Pharmaceuticals time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Eupraxia Pharmaceuticals price movement. The serial correlation of 0.05 indicates that only as little as 5.0% of current Eupraxia Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.05 | |
| Spearman Rank Test | 0.08 | |
| Residual Average | 0.0 | |
| Price Variance | 0.27 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Eupraxia Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Eupraxia Pharmaceuticals Common reported net income of (25.74 Million). This is 107.54% lower than that of the Biotechnology sector and 136.75% lower than that of the Health Care industry. The net income for all United States stocks is 104.51% higher than that of the company.
Eupraxia Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eupraxia Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eupraxia Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics of similar companies.Eupraxia Pharmaceuticals is currently under evaluation in net income category among its peers.
Eupraxia Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Eupraxia Pharmaceuticals from analyzing Eupraxia Pharmaceuticals' financial statements. These drivers represent accounts that assess Eupraxia Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Eupraxia Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Enterprise Value | 101.4M | 23.5M | 56.2M | 120.0M | 138.0M | 90.7M |
Eupraxia Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eupraxia Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eupraxia Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Eupraxia Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 372.65 M | ||||
| Shares Outstanding | 50.65 M | ||||
| Shares Owned By Insiders | 16.37 % | ||||
| Shares Owned By Institutions | 37.30 % | ||||
| Number Of Shares Shorted | 1.47 M | ||||
| Price To Book | 7.33 X | ||||
| EBITDA | (35.91 M) | ||||
| Net Income | (25.74 M) | ||||
| Total Debt | 71.86 K | ||||
| Book Value Per Share | 1.15 X | ||||
| Cash Flow From Operations | (29.99 M) | ||||
| Short Ratio | 9.07 X | ||||
| Earnings Per Share | (0.88) X | ||||
| Target Price | 14.4 | ||||
| Number Of Employees | 33 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 435 M | ||||
| Total Asset | 34.94 M | ||||
| Retained Earnings | (131 M) | ||||
| Working Capital | 31.33 M | ||||
| Net Asset | 34.94 M |
About Eupraxia Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eupraxia Pharmaceuticals Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eupraxia Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eupraxia Pharmaceuticals Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eupraxia Stock Analysis
When running Eupraxia Pharmaceuticals' price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.